Peter McWilliams, Ph.D.
Principal

Peter McWilliams is a Principal with Sanderling Ventures and has more than 15 years experience in biomedical research and management. He works with several Sanderling portfolio companies in the role of Chairman, Director, CEO and member of the management team. Portfolio companies include Trinity Biosystems, Artielle Immunotherapeutics, Actimis Pharmaceuticals, Harkness Pharmaceuticals, Cylene Pharmaceuticals and others.

Prior to joining Sanderling, Dr. McWilliams worked at Genentech (NYSE: DNA) where, as a Product Manager in Oncology Commercial Development, he managed a pipeline of oncology products in clinical and pre-clinical development and was the Commercial Team Leader for Avastin™. Prior to that he was an Associate with Booz.Allen & Hamilton in San Francisco where he focused on projects for major US and International life science companies. From 1991 to 1994 he worked for Oxford Molecular, one of the first companies in the field of rational drug design and bio-informatics where, as a Product Manager and Applications Specialist, he helped to set up and establish their US operations prior to their successful IPO on the London Stock Exchange in 1994.

Dr. McWilliams received an M.B.A. from Columbia Business School in 1996, where he was an R.C. Kopf Fellow and was elected to Beta Gamma Sigma. He received a Ph.D. in 1991 and an M.A. in 1990 in Chemistry from Princeton University where he received a Hugh Scott Taylor fellowship. He received a B.A. in Natural Sciences from Cambridge University in 1987.